Biotech Values

[CHM_760]

The XON business model reduces risk IMO.

From 2014:
Intrexon has developed a business model based on exclusive channel collaborations (ECCs) with partners. In exchange for providing access to its technology, Intrexon receives cost reimbursement (thus mitigating the need to raise additional external funds) along with significant downstream economics. This emphasizes the inherent scalability of Intrexon’s technology and maximizes long-term earnings with all its ECCs. The company has already signed over 15 ECCs including, notably, with Johnson & Johnson. Intrexon is expected to sign multiple ECCs, creating a broad pipeline of projects that diversifies single product risk.

In a nutshell: http://seekingalpha.com/article/2959066-intrexon-back-end-economics-could-generate-huge-upside